{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-032540","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.514307+00:00","generated_at":"2026-05-30T07:58:16.528250+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CervoMed to present RewinD-LB Phase 2b data at ILBDC Jan 2025; topline due Dec 2024","bullets":["Oral presentation of detailed safety/efficacy results from neflamapimod Phase 2b in DLB at ILBDC on Jan 31, 2025.","Topline results from RewinD-LB Phase 2b trial expected to be disclosed in December 2024.","CEO expresses confidence in trial design to detect statistically significant and clinically meaningful difference.","Baseline patient characteristics from RewinD-LB to be presented at CTAD conference.","No approved therapies for DLB; neflamapimod aims to address this unmet need."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-032540","json":"https://secwatch.observer/filing/0001437749-24-032540.json","markdown":"https://secwatch.observer/filing/0001437749-24-032540.md","text":"https://secwatch.observer/filing/0001437749-24-032540.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924032540/0001437749-24-032540-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924032540/crvo20241030_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T07:58:16.528250+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}